ECHA implements compliance check strategy to tighten practice on dossier updates

By Andrew MCDOUGALL

- Last updated on GMT

Copyright European Chemicals Agency
Copyright European Chemicals Agency
The European Chemicals Agency (ECHA) has implemented a new strategy for checking compliance in the hope of increasing efficiency and transparency in dossier evaluation which it hopes will reduce processing time of these documents and ensure safety.

This will be done by tightening and clarifying deadlines for dossier updates and focusing on those substances that matter the most for human health and the environment.

Transparency

As such, the Agency has started publishing a list of substances for which a compliance check would in all probability be conducted, giving registrants the possibility for early dossier updates before the compliance check starts.

However, ECHA warns that the list is indicative and non-exhaustive, meaning that it reserves the right to open further compliance checks on any dossier at any time and without prior notice to the registrants.

The proposal states that the compliance check will mainly focus on eight key endpoints which are outlined in the new compliance check strategy.

These are genotoxicity, repeated-dose toxicity, pre-natal developmental toxicity, reproduction toxicity, carcinogenicity, long-term aquatic toxicity, biodegradation and bioaccumulation endpoints.

Time saver

In order to make processing times shorter, ECHA also says that it will not take into account dossier updates after the draft decision on a compliance check has been sent to the registrant for comments.

This will not affect the 30-day period given to registrants to submit comments, will be taken into account in the decision making, on the draft decision.

“ECHA continues to offer informal interaction with registrants to clarify the process and content of the draft decision,”​ says the Agency’s announcement.

“The registrants are expected to update their dossier after the final decision, before the given deadline. ECHA will evaluate whether the requirements of the decision are met after this deadline.”

Testing proposals

The announcement continues, when registrants receive a draft decision on a testing proposal, they will have 30 days to comment and a further 30 days to update their dossier, where relevant.

To avoid unnecessary testing on vertebrate animals, a more flexible approach may on request be taken in case of testing proposals involving read-across and categories for two or more registered substances.

The applicable deadlines will be stated in ECHA's draft decision and the notification letter.

Related news

Show more

Related products

show more

Discover Peptan for Beauty & Diverse Skins

Discover Peptan for Beauty & Diverse Skins

Content provided by Rousselot | 05-Sep-2024 | Product Brochure

As beauty from within solutions soar in popularity, manufacturers need to be able to serve everyone, no matter their ethnicity or skin type.

FucoSkin®: Ocean-Inspired Sustainable Beauty

FucoSkin®: Ocean-Inspired Sustainable Beauty

Content provided by Hi-Q Marine Biotech International Ltd | 28-Aug-2024 | White Paper

FucoSkin® is a fucoidan-rich extract derived from the brown seaweed Laminaria Japonica, known for its excellent anti-aging and photoprotective benefits....

Collagen Reimagined, Discover Biodesigned Type XXI

Collagen Reimagined, Discover Biodesigned Type XXI

Content provided by Geltor | 20-Mar-2024 | Product Brochure

Collagen is the body’s most abundant protein and a mainstream ingredient for beauty. Type XXI collagen transcends a common protein into a powerful bioactive

Empowering natural barrier function for future-proof skin

Empowering natural barrier function for future-proof skin

Content provided by Lucas Meyer Cosmetics | 14-Mar-2024 | White Paper

Corneopeptyl™ is a new patented peptide biomimetic to the LCE6A protein, obtained by green chemistry-based synthesis. By mimicking the LCE6A protein activity,...

Related suppliers

Follow us

Products

View more

Webinars

Podcast